Literature DB >> 25815755

Post-SSRI Sexual Dysfunction: Clinical Characterization and Preliminary Assessment of Contributory Factors and Dose-Response Relationship.

Joseph Ben-Sheetrit1, Dov Aizenberg, Antonei B Csoka, Abraham Weizman, Haggai Hermesh.   

Abstract

Emerging evidence suggests that sexual dysfunction emerging during treatment with selective serotonin reuptake inhibitors (SSRIs) and/or serotonin-norepinephrine reuptake inhibitors (SNRIs) persists in some patients beyond drug discontinuation (post-SSRI sexual dysfunction [PSSD]). We sought to identify and characterize a series of such cases and explore possible explanatory factors and exposure-response relationship. Subjects who responded to an invitation in a forum dedicated to PSSD filled out a survey via online software. Case probability was defined according to the following 3 categories of increasing presumed likelihood of PSSD. Noncases did not meet the criteria for possible cases. Possible cases were subjects with normal pretreatment sexual function who first experienced sexual disturbances while using a single SSRI/SNRI, which did not resolve upon drug discontinuation for 1 month or longer as indicated by Arizona Sexual Experience Scale scores. High-probability cases were also younger than 50-year-olds; did not have confounding medical conditions, medications, or drug use; and had normal scores on the Hospital Anxiety and Depression Scale. Five hundred thirty-two (532) subjects completed the survey, among which 183 possible cases were identified, including 23 high-probability cases. Female sex, genital anesthesia, and depression predicted current sexual dysfunction severity, but dose/defined daily dose ratio and anxiety did not. Genital anesthesia did not correlate with depression or anxiety, but pleasureless orgasm was an independent predictor of both depression and case probability. Limitations of the study include retrospective design and selection and report biases that do not allow generalization or estimation of incidence. However, our findings add to previous reports and support the existence of PSSD, which may not be fully explained by alternative nonpharmacological factors related to sexual dysfunction, including depression and anxiety.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25815755     DOI: 10.1097/JCP.0000000000000300

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  10 in total

Review 1.  Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required.

Authors:  Robert M Nevels; Samuel T Gontkovsky; Bryman E Williams
Journal:  Psychopharmacol Bull       Date:  2016-03-01

2.  Antidepressant effects of C-Terminal domain of the heavy chain of tetanus toxin in a rat model of depression.

Authors:  Bruk Getachew; Liliana Mendieta; Antonei B Csoka; José Aguilera; Yousef Tizabi
Journal:  Behav Brain Res       Date:  2019-05-22       Impact factor: 3.332

Review 3.  Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

Authors:  Silvia Giatti; Silvia Diviccaro; Giancarlo Panzica; Roberto Cosimo Melcangi
Journal:  Endocrine       Date:  2018-04-19       Impact factor: 3.633

4.  Women's orgasm obstacles: A qualitative study.

Authors:  Maryam Nekoolaltak; Zohreh Keshavarz; Masoumeh Simbar; Ali Mohammad Nazari; Ahmad Reza Baghestani
Journal:  Int J Reprod Biomed (Yazd)       Date:  2017-08

5.  Citizen petition: Sexual side effects of SSRIs and SNRIs.

Authors:  David Healy
Journal:  Int J Risk Saf Med       Date:  2018

6.  Cutting the First Turf to Heal Post-SSRI Sexual Dysfunction: A Male Retrospective Cohort Study.

Authors:  Rosaria De Luca; Mirjam Bonanno; Alfredo Manuli; Rocco Salvatore Calabrò
Journal:  Medicines (Basel)       Date:  2022-09-01

Review 7.  Transdermal Testosterone in Female Hypoactive Sexual Desire Disorder: A Rapid Qualitative Systematic Review Using Grading of Recommendations Assessment, Development and Evaluation.

Authors:  Kavitha Ganesan; Yacob Habboush; Senan Sultan
Journal:  Cureus       Date:  2018-03-31

8.  The Effect of Citalopram on Genome-Wide DNA Methylation of Human Cells.

Authors:  Riya R Kanherkar; Bruk Getachew; Joseph Ben-Sheetrit; Sudhir Varma; Thomas Heinbockel; Yousef Tizabi; Antonei B Csoka
Journal:  Int J Genomics       Date:  2018-07-25       Impact factor: 2.326

9.  Persistent adverse effects of antidepressants.

Authors:  Joanna Moncrieff
Journal:  Epidemiol Psychiatr Sci       Date:  2019-09-23       Impact factor: 6.892

10.  Dopamine receptor agonist rotigotine-loaded microspheres ameliorates sexual function deteriorated by fluoxetine in depression rats.

Authors:  Wenqian Wang; Ce Zhang; Yiqian Fan; Shumin Yue; Yunqi Yang; Rongxia Liu; Leiming Zhang; Tian Wang; Fenghua Fu
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.